Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1285-1291

  McKenzie, Clark R ^a   Abendschein, Dana R ^a   Eisenberg, Paul R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

factor X; thrombin; thrombosis; tick anticoagulant peptide; tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; THROMBIN; THROMBOPLASTIN;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; THROMBOGENESIS;

EID: 0029816710     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1285     Document Type: Article

References (44)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:310-318.
2. Eisenberg PR. Thrombosis and fibrinolysis in acute myocardial infarction. Alcoholism din Exp Res. 1994;18:97-104.
3. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883.
4. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation. 1995;92:962-967.
5. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
6. Liu CY, Nossel HL, Kaplan K. The binding of thrombin by fibrin. J Biol Chem. 1979;254:10421-10425.
7. Lynch JJ Jr, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy: a comparison of factor Xa versus thrombin inhibition. Cardiovasc Res. 1994;28:78-85.
8. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
9. Cannon CP, MeCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993-1003.
10. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
11. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation. 1992;85:805-815.
12. Mann KG. The coagulation explosion. Ann N Y Acad Sci. 1994;714:265-269.
13. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science. 1991;253:909-912.
14. Gold HK, Torres FW, Garabedian HD, Werner W, Jang I, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21:1039-1047.
15. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
16. Abendschein D, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation. 1995;92:944-949.
17. Miletich JP, Broze GH, Majerus PW. The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, X. Anal Biochem. 1980;105:304-310.
18. Chandler AB. In vitro thrombotic coagulation of the blood. Lab Invest. 1958;7:110-114.
19. Eisenberg PR, Lee J, Miletich JP. Importance of platelets in arterial clot-associated procoagulant activity. Circulation. 1995;92(suppl I): I-803. Abstract.
20. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma. Thromb Haemost. 1991;66:529-533.
21. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation. 1985;71:912-918.
22. Kochum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A-removal of cross-reacting fibrinogen with bentonite. Thromb Res. 1980;19:589-598.
23. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pasucci I, Chiariello M, Bach R, Garen A, Königsberg WK, Ezekowitz MD. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994;74:56-63.
24. Albrecht S, Luther T, Grossman H, Flossel C, Kotzsch M, Muller M. An ELISA for tissue factor using monoclonal antibodies. Blood Coagulation Fibrinol. 1992;3:263-270.
25. Fukuda S, Iijima K, Nakamura K. Measuring tissue factor (factor III) activity in plasma. Clin Chem. 1989;35:1897-1900.
26. Iijima K, Fukuda C, Nakamura K. Measurements of tissue factor-like activity in plasma of patients with DIC. Thromb Res. 1991;61:29-38.
27. Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J. 1995;73:10-13.
28. Haskel EJ, Torr SR, Day KC, Palmier M, Wun TC, Sobel BE, Abendschein D. Prevention of arterial reocclusion after thrombolysis with lipoprotein associated coagulation inhibitor (LACI). Circulation. 1991;84:821-827.
29. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by heparin-antithrombin complex. J Clin Invest. 1983;71:1383-1391.
30. Merlini PA, Bauer KA, Ollrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
31. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol. 1991;17(6 suppl B):96B-100B.
32. Mabin TA, Holmes DR, Smith HC. Intracoronary thrombus role in coronary occlusion complicating PTCA. J Am Coll Cardiol. 1985;5:198-202.
33. Topol EJ, Fuster V, Harrington RA. Califf RM, Kleiman NS, Kereiakes DJ, Cohen-M, Chapekis A, Gold HK, Tannenbaum MA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
34. Eisenberg PR, Sherman LA, Rich M, Schwartz D, Schectman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1255-1262.
35. Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Circulation. 1992;85:928-934.
36. Hsia J, Hamilton WP, Kleiman NS, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.
37. de Bono DP, Simoons ML, Tijssen J, Arnold AER. Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group. Early intravenous heparin improves coronary patency in thrombolysis with recombinant tissue-type plasminogen activator. Br Heart J. 1992;67:122-128.
38. Bleich SD, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412-1417.
39. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM. Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. Circulation. 1994;90:613-622.
40. Nagatoma Y, Nakagawa S, Koiwaya Y, Tanaka K. Coronary angiographic ruptured atheromatous plaque as a predictor of future progression of stenosis. Am Heart J. 1990;119:1244-1253.
41. Lijia C, Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and coronary events in patient's with stabilized unstable angina. Circulation. 1995;91:2319-2324.
42. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Stevens P, Weitz J, Maraganore J, Hirsh J. Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb Haemost. 1994;72(4):523-525.
43. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel BE, Cupples LA, Braunwald E, Loscalzo J, TIMI-5 Investigators. Fibrino(geno)lytic and procoagulant markers during thrombolytic therapy with rt-PA and adjunctive antithrombotic therapy predict clinical outcomes. Circulation. 1996. In press.
44. Zoldhelyi P, Bichler J, Owen WG. Grill DE. Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation. 1994;90:2671-2678.